ArticleAnnals of surgical oncology2026
Immune-Adjusted Nodal Risk Classification After Neoadjuvant Immunotherapy for Resectable Head and Neck Cutaneous Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional nodal staging may inadequately capture posttreatment biology after neoadjuvant immunotherapy for head and neck cutaneous squamous cell carcinoma (HNcSCC). We developed an immune-adjusted nodal risk classification integrating residual viable nodal burden, residual extranodal extension (rENE), and nodal pathological response.
methodsThis single-center retrospective cohort included 82 patients with resectable HNcSCC who received at least two cycles of neoadjuvant immunotherapy followed by surgery. Residual positive lymph nodes contained viable tumor. rENE was categorized as microscopic or macroscopic, and residual viable tumor percentage was assessed in the largest residual nodal metastasis. Disease-free survival (DFS) was primary; overall survival (OS) was secondary. Prognostic performance was compared with conventional ypN stage and iN-core.
resultsAfter a median follow-up of 31.6 months, 24 DFS events and 14 deaths occurred. Nodal pathological complete response was observed in 27 patients (32.9%). Residual nodal burden showed a nonlinear association with DFS, supporting cutoffs of 0, 1, 2-3, and ≥4 residual positive lymph nodes. The final iN-risk classification defined iN-low, iN-intermediate, and iN-high groups, comprising 39 (47.6%), 22 (26.8%), and 21 (25.6%) patients, respectively. Three-year DFS decreased stepwise across groups (91.2%, 70.8%, and 25.9%; log-rank P < 0.001). Compared with iN-low disease, iN-high disease was independently associated with inferior DFS (hazard ratio 13.42; 95% confidence interval 3.85-46.77) and OS (hazard ratio 20.86; 95% confidence interval 2.65-164.34). The iN-risk model showed higher C-indexes for DFS and OS.
conclusionsAn immune-adjusted nodal risk classification based on viable residual nodal disease, rENE extent, and nodal response may improve risk stratification after neoadjuvant immunotherapy for resectable HNcSCC.
Indexed as
Identifiers
42581275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.